afliberept -一种用于vegf驱动的黄斑疾病的新型药物

Future Prescriber Pub Date : 2012-11-02 DOI:10.1002/fps.95

George Morphis MD, FEBO

{"title":"afliberept -一种用于vegf驱动的黄斑疾病的新型药物","authors":"George Morphis MD, FEBO","doi":"10.1002/fps.95","DOIUrl":null,"url":null,"abstract":"<p>Aflibercept is a novel vascular endothelial growth factor (VEGF) inhibitor that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD). In this Drug profile Mr George Morphis presents the clinical data relating to its efficacy and adverse events, and discusses its potential place in therapy. Copyright © 2012 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 2","pages":"5-7"},"PeriodicalIF":0.0000,"publicationDate":"2012-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.95","citationCount":"0","resultStr":"{\"title\":\"Aflibercept – a novel agent for VEGF-driven macular disease\",\"authors\":\"George Morphis MD, FEBO\",\"doi\":\"10.1002/fps.95\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Aflibercept is a novel vascular endothelial growth factor (VEGF) inhibitor that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD). In this Drug profile Mr George Morphis presents the clinical data relating to its efficacy and adverse events, and discusses its potential place in therapy. Copyright © 2012 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"13 2\",\"pages\":\"5-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-11-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.95\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.95\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.95","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Aflibercept – a novel agent for VEGF-driven macular disease

Aflibercept is a novel vascular endothelial growth factor (VEGF) inhibitor that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD). In this Drug profile Mr George Morphis presents the clinical data relating to its efficacy and adverse events, and discusses its potential place in therapy. Copyright © 2012 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量